Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2012, Article ID 616371, 10 pages
http://dx.doi.org/10.1155/2012/616371
Review Article

PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways

Centre de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, 43201 Reus, Spain

Received 26 July 2011; Accepted 17 October 2011

Academic Editor: J. Reddy

Copyright © 2012 Jordi Camps et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Thorp and W. S. Waring, “Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate,” Nature, vol. 194, no. 4832, pp. 948–949, 1962. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. S. L. Primo-Parmo, R. C. Sorenson, J. Teiber, and B. N. La Du, “The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family,” Genomics, vol. 33, no. 3, pp. 498–507, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. R. C. Sorenson, S. L. Primo-Parmo, S. A. Camper, and B. N. La Du, “The genetic mapping and gene structure of mouse paraoxonase/arylesterase,” Genomics, vol. 30, no. 3, pp. 431–438, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. L. C. Jaouad, C. de Guise, H. Berrougui et al., “Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydyl groups,” Atherosclerosis, vol. 185, no. 1, pp. 191–200, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Leviev, F. Negro, and R. W. James, “Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 2935–2939, 1997. View at Google Scholar · View at Scopus
  7. F. Rodríguez-Sanabria, A. Rull, R. Beltrán-Debón et al., “Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role,” Journal of Molecular Histology, vol. 41, no. 6, pp. 379–386, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. J. Ng, D. J. Wadleigh, A. Gangopadhyay et al., “Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein,” Journal of Biological Chemistry, vol. 276, no. 48, pp. 44444–44449, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. W. N. Aldridge, “Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination,” The Biochemical Journal, vol. 53, no. 1, pp. 110–117, 1953. View at Google Scholar · View at Scopus
  10. W. N. Aldridge, “Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera,” The Biochemical Journal, vol. 53, no. 1, pp. 117–124, 1953. View at Google Scholar · View at Scopus
  11. T. L. Diepgen and M. Geldmacher von Mallinckrodt, “Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism,” Archives of Toxicology, vol. 59, no. 9, pp. 154–158, 1986. View at Google Scholar · View at Scopus
  12. C. E. Furlong, “Paraoxonases: an historical perspective,” in The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism, B. Mackness, M. Mackness, M. Aviram, and G. Paragh, Eds., pp. 3–31, Springer, Dordrecht, The Netherlands, 2008. View at Google Scholar
  13. H. Davies, R. J. Richter, M. Keifer, C. Broomfield, J. Sowalla, and C. E. Furlong, “The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin,” Nature Genetics, vol. 14, no. 3, pp. 334–336, 1996. View at Google Scholar · View at Scopus
  14. H. W. Eckerson, J. Romson, C. Wyte, and B. N. La Du, “The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts,” American Journal of Human Genetics, vol. 35, no. 2, pp. 214–227, 1983. View at Google Scholar · View at Scopus
  15. H. W. Eckerson, C. M. Wyte, and B. N. La Du, “The human serum paraoxonase/arylesterase polymorphism,” American Journal of Human Genetics, vol. 35, no. 6, pp. 1126–1138, 1983. View at Google Scholar · View at Scopus
  16. S. Adkins, K. Gan, M. Mody, and B. N. La Du, “Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes,” American Journal of Human Genetics, vol. 52, no. 3, pp. 598–608, 1993. View at Google Scholar · View at Scopus
  17. M. C. Blatter Garin, R. W. James, P. Dussoix et al., “Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes,” Journal of Clinical Investigation, vol. 99, no. 1, pp. 62–66, 1997. View at Google Scholar · View at Scopus
  18. M. I. Mackness, S. Arrol, and P. N. Durrington, “Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein,” FEBS Letters, vol. 286, no. 1-2, pp. 152–154, 1991. View at Publisher · View at Google Scholar · View at Scopus
  19. M. I. Mackness, S. Arrol, C. A. Abbott, and P. N. Durrington, “Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase,” Atherosclerosis, vol. 104, no. 1-2, pp. 129–135, 1993. View at Google Scholar · View at Scopus
  20. M. Navab, J. A. Berliner, A. D. Watson et al., “The Yin and Yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff memorial lecture,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 7, pp. 831–842, 1996. View at Google Scholar · View at Scopus
  21. M. Aviram, M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du, “Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase,” Journal of Clinical Investigation, vol. 101, no. 8, pp. 1581–1590, 1998. View at Google Scholar · View at Scopus
  22. M. Aviram, S. Billecke, R. Sorenson et al., “Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 10, pp. 1617–1624, 1998. View at Google Scholar · View at Scopus
  23. M. I. Mackness, P. N. Durrington, and B. Mackness, “How high-density lipoprotein protects against the effects of lipid peroxidation,” Current Opinion in Lipidology, vol. 11, no. 4, pp. 383–388, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Ahmed, A. Ravandi, G. F. Maguire et al., “Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxvnitrite donor,” Journal of Biological Chemistry, vol. 276, no. 27, pp. 24473–24481, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Sangvanich, B. Mackness, S. J. Gaskell, P. Durrington, and M. Mackness, “The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein,” Biochemical and Biophysical Research Communications, vol. 300, no. 2, pp. 501–506, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Mertens, P. Verhamme, J. K. Bielicki et al., “Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis,” Circulation, vol. 107, no. 12, pp. 1640–1646, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. D. M. Shih, L. Gu, Y. R. Xia et al., “Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis,” Nature, vol. 394, no. 6690, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. D. M. Shih, Y. R. Xia, E. Miller et al., “Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis,” Journal of Biological Chemistry, vol. 275, no. 23, pp. 17527–17535, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Tward, Y. R. Xia, X. P. Wang et al., “Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice,” Circulation, vol. 106, no. 4, pp. 484–490, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. M. N. Oda, J. K. Bielicki, T. T. Ho, T. Berger, E. M. Rubin, and T. M. Forte, “Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins,” Biochemical and Biophysical Research Communications, vol. 290, no. 3, pp. 921–927, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Aviram, M. Rosenblat, S. Billecke et al., “Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants,” Free Radical Biology and Medicine, vol. 26, no. 7-8, pp. 892–904, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. O. Rozenberg and M. Aviram, “S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity,” Biochemical and Biophysical Research Communications, vol. 351, no. 2, pp. 492–498, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Jakubowski, “Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation,” Journal of Biological Chemistry, vol. 275, no. 6, pp. 3957–3962, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. J. F. Teiber, D. I. Draganov, and B. N. La Du, “Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3,” Biochemical Pharmacology, vol. 66, no. 6, pp. 887–896, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Biggadike, R. M. Angell, C. M. Burgess et al., “Selective plasma hydrolysis of glucocorticoid γ-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism,” Journal of Medicinal Chemistry, vol. 43, no. 1, pp. 19–21, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. B. N. La Du, M. Aviram, S. Billecke et al., “On the physiological role(s) of the paraoxonases,” Chemico-Biological Interactions, vol. 119-120, pp. 379–388, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Harel, A. Aharoni, L. Gaidukov et al., “Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes,” Nature Structural and Molecular Biology, vol. 11, no. 5, pp. 412–419, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. O. Khersonsky, C. Roodveldt, and D. S. Tawfik, “Enzyme promiscuity: evolutionary and mechanistic aspects,” Current Opinion in Chemical Biology, vol. 10, no. 5, pp. 498–508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. R. A. Jensen, “Enzyme recruitment in evolution of new function,” Annual Review of Microbiology, vol. 30, pp. 409–425, 1976. View at Google Scholar · View at Scopus
  40. U. T. Bornscheuer and R. J. Kazlauskas, “Catalytic promiscuity in biocatalysis: using old enzymes to form new bonds and follow new pathways,” Angewandte Chemie, vol. 43, no. 45, pp. 6032–6040, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. S. D. Copley, “Enzymes with extra talents: moonlighting functions and catalytic promiscuity,” Current Opinion in Chemical Biology, vol. 7, no. 2, pp. 265–272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. R. J. Kazlauskas, “Enhancing catalytic promiscuity for biocatalysis,” Current Opinion in Chemical Biology, vol. 9, no. 2, pp. 195–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. P. J. O'Brien and D. Herschlag, “Catalytic promiscuity and the evolution of new enzymatic activities,” Chemistry and Biology, vol. 6, no. 4, pp. R91–R105, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Aharoni, G. Amitai, K. Bernath, S. Magdassi, and D. S. Tawfik, “High-throughput screening of enzyme libraries: thiolactonases evolved by fluorescence-activated sorting of single cells in emulsion compartments,” Chemistry and Biology, vol. 12, no. 12, pp. 1281–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Aharoni, L. Gaidukov, O. Khersonsky, S. M. Gould, C. Roodveldt, and D. S. Tawfik, “The “evolvability” of promiscuous protein functions,” Nature Genetics, vol. 37, no. 1, pp. 73–76, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Aharoni, L. Gaidukov, S. Yagur, L. Toker, I. Silman, and D. S. Tawfik, “Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 2, pp. 482–487, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. O. Khersonsky and D. S. Tawfik, “Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase,” Biochemistry, vol. 44, no. 16, pp. 6371–6382, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Tavori, S. Khatib, M. Aviram, and J. Vaya, “Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity,” Bioorganic and Medicinal Chemistry, vol. 16, no. 15, pp. 7504–7509, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. O. Khersonsky and D. S. Tawfik, “The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases,” Journal of Biological Chemistry, vol. 281, no. 11, pp. 7649–7656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Rosenblat, L. Gaidukov, O. Khersonsky et al., “The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux,” Journal of Biological Chemistry, vol. 281, no. 11, pp. 7657–7665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Bourquard, D. M. Shih, and C. J. Ng et al, “The role of PON2 and PON3 in atherosclerosis and related trait,” in The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism, B. Mackness, M. Mackness, M. Aviram, and G. Paragh, Eds., pp. 103–128, Springer, Dordrecht, The Netherlands, 2008. View at Google Scholar
  52. S. T. Reddy, D. J. Wadleigh, V. Grijalva et al., “Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 4, pp. 542–547, 2001. View at Google Scholar · View at Scopus
  53. D. Draganov, P. L. Stetson, C. E. Watson, S. Billecke, and B. N. La Du, “Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation,” Journal of Biological Chemistry, vol. 275, no. 43, pp. 33435–33442, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Paragh, M. Harangi, and I. Seres, “Effect of lipid lowering medications in PON1,” in The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism, B. Mackness, M. Mackness, M. Aviram, and G. Paragh, Eds., pp. 251–266, Springer, Dordrecht, The Netherlands, 2008. View at Google Scholar
  55. P. N. Durrington, M. I. Mackness, D. Bhatnagar et al., “Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia,” Atherosclerosis, vol. 138, no. 1, pp. 217–225, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. V. Tsimihodimos, A. Kakafika, A. P. Tambaki et al., “Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins,” Journal of Lipid Research, vol. 44, no. 5, pp. 927–934, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Paragh, I. Seres, M. Harangi et al., “The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease,” Diabetes and Metabolism, vol. 29, no. 6, pp. 613–618, 2003. View at Google Scholar · View at Scopus
  58. G. Paragh, I. Seres, M. Harangi et al., “Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome,” British Journal of Clinical Pharmacology, vol. 61, no. 6, pp. 694–701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. Z. Ackerman, M. Oron-Herman, T. Rosenthal et al., “Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver,” Digestive Diseases and Sciences, vol. 53, no. 3, pp. 777–784, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. W. Phuntuwate, C. Suthisisang, B. Koanantakul, P. Chaloeiphap, B. Mackness, and M. Mackness, “Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels,” Atherosclerosis, vol. 196, no. 1, pp. 122–128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Gouédard, N. Koum-Besson, R. Barouki, and Y. Morel, “Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins,” Molecular Pharmacology, vol. 63, no. 4, pp. 945–956, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. P. Raskin, E. B. Rappaport, S. T. Cole, Y. Yan, R. Patwardhan, and M. I. Freed, “Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes,” Diabetologia, vol. 43, no. 3, pp. 278–284, 2000. View at Google Scholar · View at Scopus
  63. J. P. van Wijk, E. J. de Koning, M. C. Cabezas, and T. J. Rabelink, “Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes,” Diabetes Care, vol. 28, no. 4, pp. 844–849, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. B. Chappuis, M. Braun, C. Stettler et al., “Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study,” Diabetes/Metabolism Research and Reviews, vol. 23, no. 5, pp. 392–399, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. J. van Wijk, B. Coll, M. C. Cabezas et al., “Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients,” Clinical and Experimental Pharmacology and Physiology, vol. 33, no. 12, pp. 1134–1137, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Mulligan, Y. Yang, D. A. Wininger et al., “Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio,” AIDS, vol. 21, no. 1, pp. 47–57, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. B. Coll, J. P. H. van Wijk, S. Parra et al., “Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy,” European Journal of Pharmacology, vol. 544, no. 1–3, pp. 104–110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. J. A. Menendez, S. Cufí, C. Oliveras-Ferraros, L. Vellon, J. Joven, and A. Vazquez-Martin, “Gerosuppressant metformin: less is more,” Aging, vol. 3, no. 4, pp. 348–362, 2011. View at Google Scholar
  69. M. Tomás, M. Sentí, F. García-Faria et al., “Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 9, pp. 2113–2119, 2000. View at Google Scholar · View at Scopus
  70. Y. Shen, H. Wu, C. Wang et al., “Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor γ,” European Journal of Pharmacology, vol. 649, no. 1–3, pp. 255–262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. J. A. Wang, W. A. Chen, Y. Wang et al., “Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms,” Atherosclerosis, vol. 217, no. 1, pp. 90–96, 2011. View at Publisher · View at Google Scholar
  72. M. Harangi, I. Seres, Z. Varga et al., “Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage,” European Journal of Clinical Pharmacology, vol. 60, no. 10, pp. 685–691, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Kassai, L. Illyés, H. Z. Mirdamadi et al., “The effect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase,” Clinical Biochemistry, vol. 40, no. 1-2, pp. 1–5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. I. M. Bolayirli, M. Aslan, H. Balci, T. Altug, M. Hacibekiroglu, and A. Seven, “Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine,” Life Sciences, vol. 81, no. 2, pp. 121–127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. S. C. Bergheanu, A. Van Tol, G. M. Dallinga-Thie et al., “Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol,” Current Medical Research and Opinion, vol. 23, no. 9, pp. 2235–2240, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Mirdamadi, F. Sztanek, Z. Derdak, I. Seres, M. Harangi, and G. Paragh, “The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters,” British Journal of Clinical Pharmacology, vol. 66, no. 3, pp. 366–374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Shiner, B. Fuhrman, and M. Aviram, “Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPARγ and AP-1 pathway activation,” Atherosclerosis, vol. 195, no. 2, pp. 313–321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Khateeb, A. Gantman, A. J. Kreitenberg, M. Aviram, and B. Fuhrman, “Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-γ pathway,” Atherosclerosis, vol. 208, no. 1, pp. 119–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Marsillach, J. Camps, N. Ferré et al., “Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease,” BMC Gastroenterology, vol. 9, article 3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233–241, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. R. Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362, no. 6423, pp. 801–809, 1993. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Mackness, D. Hine, Y. Liu, M. Mastorikou, and M. Mackness, “Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells,” Biochemical and Biophysical Research Communications, vol. 318, no. 3, pp. 680–683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Rull, R. García, L. Fernández-Sender et al., “The role of combined assessment of defense against oxidative stress and inflammation in the evaluation of peripheral arterial disease,” Current Molecular Medicine, vol. 11, no. 6, pp. 453–464, 2011. View at Google Scholar
  84. A. Rull, J. Camps, C. Alonso-Villaverde, and J. Joven, “Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (orCCL2) in the regulation of metabolism,” Mediators of Inflammation, vol. 2010, Article ID 326580, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. J. X. Rong, J. W. Berman, M. B. Taubman, and E. A. Fisher, “Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 10, pp. 1617–1623, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Rull, R. Beltrán-Debón, G. Aragonès et al., “Expression of cytokine genes in the aorta is altered by the deficiency in MCP-1: effect of a high-fat, high-cholesterol diet,” Cytokine, vol. 50, no. 2, pp. 121–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. C. H. Hsing, W. Chou, J. J. Wang, H. W. Chen, and C. H. Yeh, “Propofol increases bone morphogenetic protein-7 and decreases oxidative stress in sepsis-induced acute kidney injury,” Nephrology Dialysis Transplantation, vol. 26, no. 4, pp. 1162–1172, 2011. View at Publisher · View at Google Scholar
  88. C. C. Chuang, K. Martínez, and G. Xie et al, “Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor alpha-mediated inflammation and insulin resistance in primary human adipocytes,” American Journal of Clinical Nutrition, vol. 92, pp. 1511–1521, 2010. View at Google Scholar
  89. D. Wang, A. Haile, and L. C. Jones, “Rosiglitazone-induced adipogenesis in a bone marrow mesenchymal stem cell line—biomed 2011,” Biomedical Sciences Instrumentation, vol. 47, pp. 213–221, 2011. View at Google Scholar
  90. W. M. Wang, H. Chen, F. Zhong, Y. Lu, L. Han, and N. Chen, “Inhibitory effects of rosiglitazone on lipopolysaccharide-induced inflammation in a murine model and HK-2 cells,” American Journal of Nephrology, vol. 34, no. 2, pp. 152–162, 2011. View at Publisher · View at Google Scholar
  91. T. Matsumura, H. Kinoshita, N. Ishii et al., “Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 6, pp. 1268–1275, 2011. View at Publisher · View at Google Scholar
  92. M. E. Marketou, J. E. Kontaraki, N. A. Tsakountakis et al., “Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension,” American Journal of Cardiology, vol. 107, no. 1, pp. 59–63, 2011. View at Publisher · View at Google Scholar · View at Scopus